Sale!

AML Panel Cytogenetics FISH Analysis

Original price was: $600.Current price is: $450.

-25%

The AML Panel Cytogenetics FISH Analysis is a comprehensive genetic test specifically designed for diagnosing and monitoring acute myeloid leukemia (AML). This advanced test combines cytogenetic analysis with fluorescence in situ hybridization (FISH) technology to detect critical genetic abnormalities including AML/ETO fusion, inv(16), PML/RARA rearrangement, and MLL gene rearrangements. These specific genetic markers are essential for accurate AML diagnosis, risk stratification, and treatment selection. The test provides crucial information that helps hematologists determine the most effective therapeutic approach and predict patient prognosis. With a 10-day turnaround time and priced at $450 USD, this specialized panel offers invaluable insights for managing AML patients throughout their treatment journey.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

AML Panel Cytogenetics FISH Analysis

Comprehensive Genetic Testing for Acute Myeloid Leukemia

The AML Panel Cytogenetics FISH Analysis represents a cutting-edge diagnostic approach for patients with suspected or confirmed acute myeloid leukemia. This sophisticated genetic test combines traditional cytogenetic methods with advanced fluorescence in situ hybridization (FISH) technology to provide a comprehensive assessment of chromosomal abnormalities associated with AML. By detecting specific genetic rearrangements that drive leukemia development, this panel enables precise diagnosis, accurate risk stratification, and personalized treatment planning.

What This Test Measures and Detects

Our AML Panel specifically targets four critical genetic abnormalities that are clinically significant in AML diagnosis and management:

  • AML/ETO Fusion Gene: Detects the t(8;21) translocation creating the AML1-ETO fusion protein
  • inv(16) Abnormality: Identifies inversion of chromosome 16 associated with core-binding factor AML
  • PML/RARA Rearrangement: Screens for t(15;17) translocation characteristic of acute promyelocytic leukemia
  • MLL Gene Rearrangements: Detects abnormalities in the mixed lineage leukemia gene on chromosome 11q23

Who Should Consider This Test

This comprehensive genetic panel is recommended for individuals presenting with:

  • Unexplained cytopenias (low blood counts) including anemia, thrombocytopenia, or neutropenia
  • Suspected acute myeloid leukemia based on peripheral blood or bone marrow findings
  • Newly diagnosed AML patients requiring genetic risk stratification
  • Patients with recurrent fever, fatigue, bruising, or bleeding tendencies
  • Individuals with abnormal white blood cell counts or blast cells in circulation
  • Patients requiring treatment monitoring and minimal residual disease assessment

Clinical Benefits of AML Genetic Testing

Undergoing the AML Panel Cytogenetics FISH Analysis provides numerous clinical advantages:

  • Accurate Diagnosis: Confirms AML subtype and identifies specific genetic drivers
  • Risk Stratification: Determines prognostic risk category (favorable, intermediate, poor)
  • Treatment Guidance: Informs selection of targeted therapies and treatment intensity
  • Prognostic Information: Provides valuable insights into disease course and outcomes
  • Monitoring Capability: Enables tracking of treatment response and disease progression
  • Personalized Medicine: Supports development of individualized treatment strategies

Understanding Your Test Results

Your AML Panel results will provide detailed information about the presence or absence of specific genetic abnormalities:

  • Positive for Genetic Abnormalities: Indicates the presence of one or more targeted genetic rearrangements, which helps classify your AML subtype and guide treatment decisions
  • Negative Results: Suggests absence of the specific abnormalities tested, though other genetic changes may be present
  • Risk Category Assignment: Results help categorize your AML into favorable, intermediate, or poor risk groups
  • Treatment Implications: Specific genetic findings may indicate responsiveness to particular targeted therapies

It’s essential to discuss your results with your hematologist or oncologist, who will interpret them in the context of your complete clinical picture and develop an appropriate treatment plan.

Test Pricing Information

Test Component Price (USD)
Discount Price $450
Regular Price $600

Test Specifications

  • Turnaround Time: 10 days
  • Sample Type: Bone marrow / Peripheral blood (Transport immediately)
  • Test Components: Sodium Heparin Vacutainer (2ml)
  • Methodology: Cell Culture + FISH (Fluorescence In Situ Hybridization)

Pre-Test Instructions

The AML Panel (Cytogenetics + FISH [AML/ETO, inv(16), PML/RARA, MLL]) requires a Doctor’s prescription. Please note that prescriptions are not applicable for surgery and pregnancy cases or individuals planning to travel abroad.

Nationwide Availability

We have branches across all major cities in the United States, ensuring convenient access to this specialized genetic testing. Our network includes locations in New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose, with additional centers throughout the country.

Book Your Test Today

Take the first step toward precise AML diagnosis and personalized treatment planning. Our expert genetic counselors and hematology specialists are ready to assist you with comprehensive genetic analysis and interpretation.

Call or WhatsApp us today at +1(267) 388-9828 to schedule your AML Panel Cytogenetics FISH Analysis and receive the genetic insights needed for optimal leukemia management.